Repare Therapeutics (RPTX) to Release Quarterly Earnings on Wednesday

Repare Therapeutics (NASDAQ:RPTX) will likely be issuing its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.77) per share for the quarter.

Repare Therapeutics Stock Performance

RPTX opened at $1.29 on Monday. Repare Therapeutics has a one year low of $1.10 and a one year high of $7.45. The stock has a market capitalization of $54.84 million, a PE ratio of -0.65 and a beta of 0.88. The business’s 50 day moving average price is $1.28 and its 200 day moving average price is $2.54.

Analyst Ratings Changes

RPTX has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Repare Therapeutics in a research note on Friday, November 8th. Lifesci Capital restated a “market perform” rating on shares of Repare Therapeutics in a research note on Friday, December 13th. Bloom Burton cut Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 10th. Finally, Stifel Nicolaus decreased their price target on Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, December 13th.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.